Eckert & Ziegler: European Commission Confirms European Approval for YTTRIGA

BERLIN, January 21, 2011 /PRNewswire-FirstCall/ -- Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a firm specializing in radioactive compounds for the treatment of cancer, has renewed the approval of its drug YTTRIGA (Yttrium-90 chloride) by the European Commission. Five years ago the European Medicines Agency EMA approved this drug for the first time and as a result of the current renewal process the drug has now been granted an indefinite approval.

YTTRIGA is used as an active component in the preparation of numerous radiopharmaceuticals for the treatment of liver, intestinal and blood cancers as well as for neuroendocrine tumours. YTTRIGA is coupled with a tumour-specific peptide or with an antibody which recognizes cancer cells and binds to them maximizing the dose of ionizing radiation to the cancerous cells and minimizing radiation exposure to healthy cells.

Pharmaceutical grade YTTRIGA is produced under cGMP in Eckert & Ziegler's clean room facility in Braunschweig, from which it is shipped worldwide to radiopharmacy facilities that use it in radiolabeling preparations.

The Eckert & Ziegler Group of Companies has around 540 employees is one of the world's largest providers of isotope technology for radiotherapy and nuclear medicine.

The Board of Directors

If you have any questions please contact:

Eckert & Ziegler AG, Karolin Riehle, Investor Relations, Robert-Rossle-Str. 10, 13125 Berlin, Phone: +49(0)30-94-10-84-138, Fax -112, e-mail: [email protected], http://www.ezag.de

SOURCE Eckert & Ziegler AG

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED